ED Attaches Sresan Pharma Owner Assets
Analysis based on 9 articles · First reported Dec 03, 2025 · Last updated Dec 03, 2025
The event highlights significant regulatory failures and corporate malfeasance within the pharmaceutical industry, potentially leading to increased scrutiny and stricter regulations on drug manufacturing and quality control in India. This could impact the stock prices of pharmaceutical companies, particularly those with questionable manufacturing practices, and may lead to a decline in investor confidence in the sector.
The India — Enforcement Directorate provisionally attached immovable properties worth 2.04 crore belonging to G. Ranganathan, proprietor of Sresan Pharmaceuticals, in connection with the killer cough syrup case. The company is accused of using industrial-grade raw materials instead of pharma-grade materials to produce the cough syrup Coldrif, which led to the death of 22 children in India — Madhya Pradesh. The investigation also uncovered corruption within the United States — Food and Drug Administration, with its director P. U. Karthigeyan named in an FIR for alleged corruption and later arrested. The cough syrup was found to contain high concentrations of toxic chemicals, Diethylene glycol and Diethylene glycol, far beyond safe limits. The India — Enforcement Directorate's probe stems from FIRs registered by the India — Madhya Pradesh Police and Chennai's police anti-corruption branch, highlighting widespread malpractice and regulatory lapses.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard